HIV-1 RECOMBINANT GP160 VACCINE-INDUCED ANTIBODIES IN SERUM AND SALIVA

As part of a phase I safety and immunogenicity trial of a vaccinia-exp ressed HIV-1 recombinant gp160 (rgp160) candidate vaccine, we measured serum and saliva antibody responses in low risk, uninfected volunteer s. Six healthy adult volunteers received 50 mu g doses of rgp160 vacci ne adjuvanted in alum and deoxycholate at months 0, 1, 6, and 12. A 20 0 mu g rgp160 immunization was given to four volunteers at 18 months. The vaccine induced anti-envelope glycoprotein IgG and IgA serum antib odies in all six volunteers. Saliva antibodies to envelope glycoprotei n appeared in some volunteers at certain timepoints. Three volunteers appeared to transiently develop vaccine-induced secretory IgA antibody to envelope glycoprotein in whole saliva.